ライフサイエンスコーパス: nmol

1 ants with >0.5-1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95% CI): 1.04 (0.92, 1.17)].

2 ause mortality compared with those with >1.0 nmol/L [fully adjusted HR (95% CI): 1.19 (1.03, 1.38)].

3 sk was similar in participants with >0.5-1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95%

4 L: <=0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L, 1.02 (0.86, 1.20)].

5 es and categorized as <=0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L.

6 d as <=0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L.

7 [fully adjusted HR (95% CI) relative to >1.0 nmol/L: <=0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L

8 osterone (7.6 nmol/L; normal range, 8.0-29.0 nmol/L).

9 amin D3 and placebo group were 30.7 and 30.0 nmol/L, with status increasing by 70.5 nmol/L and 5.3 nm

10 women had lower 25(OH)D (median 13.0 vs 36.0 nmol/L), higher PTH (median 7.7 vs 3.3 pmol/L) and simil

11 mol/L) and in women (35.3 compared with 37.0 nmol/L), whereas RBC folate showed no significant change

12 de (increase 133.0 +/- 80.5 vs 54.3 +/- 47.0 nmol/g), pH (increase 1.3 +/- 0.5 vs 0.9 +/- 0.6), and t

13 mo to a mean 25(OH)D of 55.9, 64.6, or 79.0 nmol/L for participants receiving a monthly dose of 12,0

14 etylcholine receptor antibody titres of 1.00 nmol/L or higher (or concentrations of 0.50-0.99 nmol/L

15 , and beta-caryophyllene (0.0025 +/- 0.00080 nmol/mug), highlighting the potential importance of OH-i

16 .0050 nmol/mug), limonene (0.0059 +/- 0.0010 nmol/mug), and beta-caryophyllene (0.0025 +/- 0.00080 nm

17 ozonolysis of alpha-pinene (0.020 +/- 0.0050 nmol/mug), limonene (0.0059 +/- 0.0010 nmol/mug), and be

18 -1)), but a sink for N(2)O (-0.016 +/- 0.008 nmol m(-2) s(-1)).

19 mpared to normoalbuminuria (0.0442 vs 0.0103 nmol/mg creatinine, P < 0.0001), and increased ca. three

20 The sensor sensitivity was 0.015 nmol carbonyl per mg of oxidized protein and detection l

21 o patients with stable GFR (0.0561 vs 0.0176 nmol/mg creatinine, P < 0.01).

22 lowly photodegraded in seawater (~0.001-0.03 nmol L(-1) h(-1)), whereas acetaldehyde and glyoxal were

23 c properties of MVT-602 (doses 0.01 and 0.03 nmol/kg) versus KP54 (9.6 nmol/kg) in the follicular pha

24 52, reaching 0.08 nmol/g (gadobutrol), 0.04 nmol/g (gadoterate meglumine), and 0.07 nmol/g (gadoteri

25 Mice injected with 0.05 nmol/g bodyweight of the conjugate (AlexaFFA) were subje

26 nged from 0.35-0.79, 0.06-0.2, and 0.02-0.07 nmol L(-1) h(-1) for acetaldehyde, glyoxal, and methylgl

27 0.04 nmol/g (gadoterate meglumine), and 0.07 nmol/g (gadoteridol).

28 reased between weeks 5 and 52, reaching 0.08 nmol/g (gadobutrol), 0.04 nmol/g (gadoterate meglumine),

29 8.0-35.2; p<0.0001) and reverse T(3) by 0.08 nmol/L (0.05-0.10; p<0.0001).

30 asma 25(OH)D concentration was 68.7 +/- 19.1 nmol/L.

31 D [25(OH)D] concentration was 40.0 +/- 20.1 nmol/L, which increased after 12 mo to a mean 25(OH)D of

32 ure to tumor (target tissue; AUC(0- t) = 5.1 nmol h/g) versus GI tissues (toxicity tissue; AUC(0- t)

33 MFA) > 1 nmol/L or serum total folate > 74.1 nmol/L, and low vitamin B-12 status as methylmalonic aci

34 as unmetabolized serum folic acid (UMFA) > 1 nmol/L or serum total folate > 74.1 nmol/L, and low vita

35 statin therapy, an increase in 25(OH)D of 1 nmol/L was associated with a 0.01 unit reduction in TC:H

36 For example, less than 1 nmol sulfate is required to determine (18)O/(34)S ratios

37 espectively after 6 h) than MGO (2.6 and 3.1 nmoles/mg protein at the same sampling point).

38 increase and 0.07 (95% CI: 0.00, 0.44) per 1-nmol DTT/min/m3 oxidative potential increase].

39 0.009 mL/g/min; receptor density, 18 +/- 10 nmol/L) were obtained for strategy 3.

40 uman arterioles incubated with adenosine (10 nmol/L) or ADK inhibitor ABT-702 (0.1 umol/L) both displ

41 duration at 90% repolarization and after 10 nmol/L isoproterenol compared with WT (n=7; P<0.05).

42 01-0.1 mL/g/min) and receptor density (1-100 nmol/L).

43 ns to cell death at concentrations above 100 nmol/L.

44 enol perfusion (at 30 nmol/L, n=7/12 and 100 nmol/L n=8/12 hearts without EADs and PVTs).

45 ive to the specific SK inhibitor apamin (100 nmol L(-1) ), which was eliminated by inhibition of PKA

46 hearts in control versus 1/14 hearts at 100 nmol/L) without altering action potential duration or re

47 ivatives, many of which were present in >100 nmol amounts and were sequenced by sequential MS fragmen

48 a-adrenergic stimulation (isoproterenol, 100 nmol L(-1) ) evoked I(SK) in VMs from Shams, resulting i

49 ndard treatment (4 cycles of 7.4 GBq and 105 nmol), a treatment maximizing the number of cycles based

50 n observational analyses for a 50 mg/dl (105 nmol/l) higher lipoprotein(a) level the age- and sex-adj

51 f detection and quantification of 32 and 106 nmol L(-1), respectively.

52 r, at 0.022 +/- 0.012 mL/g/min and 21 +/- 11 nmol/L, respectively.

53 m post-LAAC (144 [48-192] versus 52 [24-111] nmol/L, P=0.062 for F1+2; 299 [254-390] versus 78 [19-24

54 s with morning total serum testosterone 7-12 nmol/l were recruited.

55 ivors with borderline low testosterone (7-12 nmol/l).

56 (4x12Q4W), or grass allergen peptides at 12 nmol at 2-week intervals for a total of 8 doses (8x12Q2W

57 oses (8x6Q2W), grass allergen peptides at 12 nmol at 4-week intervals for a total of 4 doses (4x12Q4W

58 Accordingly, risk >/=120 nmol/L could not be evaluated (i.e., n = 7 and ndeaths =

59 tatus (C-reactive protein >3.0 mug/mL or 120 nmol/L), respectively.

60 f 25-hydroxyvitamin D (25[OH]D) of 30 to 125 nmol/L.

61 ebellum were 3.38 nmol/g (gadodiamide), 2.13 nmol/g (gadopentetate dimeglumine), and 1.91 nmol/g (gad

62 [Pyr(1)]apelin-13 (135 nmol/min) was infused into six healthy human volunteers

63 upplementation increased mean 25(OH)D to 135 nmol/L at 3 years, while those on placebo remained at 63

64 supplementation increased mean 25OHD to 135 nmol/L at 3 years, while those on placebo stayed at 63 n

65 mol/L higher than nonconsumers (n = 229) (14 nmol/L; 95% CI: 12, 16 nmol/L) (P < 0.001).

66 up and 11.4+/-5.6 ng per milliliter (28+/-14 nmol per liter) in the placebo group (difference, 35.5 n

67 mol/L (0.69) at month 12 (mean decrease 3.15 nmol/L, 95% CI 2.68-3.62; p<0.0001), while serum TSH con

68 levels of at least 60 mg per deciliter (150 nmol per liter).

69 a C-reactive protein level of 159 mg/L (1514 nmol/L) (normal value, <8.0 mg/L [76.2 nmol/L]), and a w

70 nsumers (n = 229) (14 nmol/L; 95% CI: 12, 16 nmol/L) (P < 0.001).

71 rvention group to a mean +/- SD of 85 +/- 16 nmol/L compared with 43 +/- 18 nmol/L in the placebo gro

72 baseline Lp(a) concentration was 37 (13-165) nmol/L.

73 7 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), with a mean difference of 0.67 nmol/mmol (95

74 ive HCV (P = .002); however, low FT (<0.1735 nmol/L) was common (50% active HCV, 43% SVR) and did not

75 ); mean +/- 95% CI) and CH(4) (0.37 +/- 0.18 nmol m(-2) s(-1)), but a sink for N(2)O (-0.016 +/- 0.00

76 of 85 +/- 16 nmol/L compared with 43 +/- 18 nmol/L in the placebo group after 6 mo (P < 0.001).

77 ls with lipoprotein(a) levels <10 mg/dl (<18 nmol/l: first to 50th percentile), the multivariable-adj

78 entile for serum (~70 nmol/L) and RBC (~1800 nmol/L) folate in supplement nonusers aged >=60 y was si

79 ls with lipoprotein(a) levels >93mg/dl (>199 nmol/L: 96th to 100th percentile).

80 on and lipoprotein(a) levels >93 mg/dl (>199 nmol/l: 96th to 100th percentile).

81 amin D concentrations (154.5 nmol/L vs. 15.2 nmol/L in active vs. placebo arms, respectively; 95% con

82 e, HDL rapidly acquired d6-alpha-T (21 +/- 2 nmol/L plasma per minute).

83 al and peripheral nervous tissues (1.8-333.2 nmol Gd/g tissue).

84 (1514 nmol/L) (normal value, <8.0 mg/L [76.2 nmol/L]), and a white cell count of 7 x 10(9)/L (normal

85 respectively, but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstr

86 0.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

87 0.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

88 els of <2 nmol 1/2 cystine/mg protein or >=2 nmol 1/2 cystine/mg protein, respectively).

89 sis of white blood cell cystine levels of <2 nmol 1/2 cystine/mg protein or >=2 nmol 1/2 cystine/mg p

90 ose of metformin (therapeutic equivalent: <2 nmol/mg) caused a more oxidized mitochondrial NADH/NAD s

91 3 mL/g/min and receptor density of 34 +/- 20 nmol/L were determined for the 9 virtual patients.

92 on was strongest at PLP concentrations < ~20 nmol/L, a recognized threshold for vitamin B-6 deficienc

93 itamin B-6 deficiency was defined as PLP <20 nmol/L, and insufficiency as PLP 20-30 nmol/L.

94 g DCCT/EDIC (hazard ratio [HR] = 1.16 per 20 nmol/L higher levels of plasma kallikrein; P = 0.0177) a

95 tracerebroventricular injection of RG108 (20 nmol/day per 5 days), similar to the systemic administra

96 XC, but in a 10 times higher sensitivity, 20 nmol L(-1), for CFD.

97 (n = 1017) among supplement nonusers was 20 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L highe

98 mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encep

99 either 200 nmol of AGS-v vaccine alone, 200 nmol of AGS-v with adjuvant (Montanide ISA 51), or steri

100 ation sequence, to treatment with either 200 nmol of AGS-v vaccine alone, 200 nmol of AGS-v with adju

101 We found that PCoA concentration < 200 nmol/mg mito protein resulted in low H2O2 emission flux,

102 Torin1 (0 to 200 nmol/L) was used to inhibit the mTOR pathway at various

103 Torin1 (200 nmol/L) increased the percentage of quiescent cells (G(0

104 ement nonusers was 20 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L higher than nonconsumers (n

105 ooplankton REE concentrations (EREEY 3.2-210 nmol g(-1)).

106 y 600 nmol m(-2) and of methylmercury by 214 nmol m(-2) in the Gotland Deep, probably via attachment

107 detection and quantification of 72.6 and 220 nmol L(-1), respectively.

108 (means +/- SEM: 382 +/- 35 versus 73 +/- 24 nmol L(-1) d(-1) , Mann-Whitney U-test p < 0.0001), and

109 hydroxyvitamin D [25(OH)D] level was 63 (24) nmol/L; 25% were <50 nmol/L.

110 5-hydroxyvitamin D (25OHD) level was 63 (24) nmol/L; 25% were <50 nmol/L.

111 up to H2O2 generation rates ~50 muM/s (0.25 nmol/mg-protein/s), above which point the Prx3 system wo

112 en fused to human Fc domain (TXB2-hFc) at 25 nmol/kg (1.875 mg/kg) in mice resulted in rapid binding

113 c fused with neurotensin (TXB2-hFc-NT) at 25 nmol/kg resulted in a rapid and reversible pharmacologic

114 severe vitamin D deficiency as 25-(OH)D < 25 nmol/L and performed stratified analyses by HIV status i

115 Neonatal 25OHD < 25 nmol/L was associated with 1.33 times higher odds of ASD

116 bset of 1064 adult individuals, 25(OH)D < 25 nmol/L was associated with a reduction in DEXA-measured

117 Vitamin D deficiency (<25 nmol/L ~ 10 ng/mL) shortened survival in primary melanom

118 05) and HVA concentrations by a median of 25 nmol/L (IQR 11-48; p=0.012); however, there was no signi

119 In contrast, APOE at concentrations of 25 nmol/L or greater induced nucleotide-binding oligomeriza

120 ipants with baseline 25(OH)D of less than 25 nmol/L (aIRR 0.33, 0.11-0.98; p=0.046; 92 participants i

121 Also, every 25-nmol/L 25(OH)D in infancy was associated with an adjuste

122 Every 25-nmol/L difference in 25(OH)D was related to an adjusted

123 Biodistribution of (18)F-AlF-PSMA-11 (0.26 nmol/mouse, 8-9 MBq/mouse) in male BALB/c nude mice with

124 a high coverage of electroactive sites (270 nmol cm(-2)) and a high current density (-16.5 mA cm(-2)

125 amin B-12 status as methylmalonic acid > 271 nmol/L or serum vitamin B-12 < 150 pmol/L.

126 lasma vitamin B-12 < 148 pmol/L or MMA > 271 nmol/L), but none were folate deficient (plasma folate <

127 carboxylic acid groups on the surface (11.3 nmol/cm(2)), a value comparable to three-dimensional mat

128 Samples containing 2-3 nmol Cl injected on-column were sufficient to achieve a

129 mol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showed significant monthly variation (P < 0

130 ith status increasing by 70.5 nmol/L and 5.3 nmol/L, respectively (between-group difference in vitami

131 5% CI: 24.7, 25.0) and mean 25(OH)D was 50.3 nmol/L (95% CI: 49.8, 50.7 nmol/L).

132 n vitamin D: 65.8 nmol/L; 95% CI: 54.2, 77.3 nmol/L; P < 0.01), after supplementation.

133 tic experiments produced 209+/-30 nmol NH(3) nmol MoFe(-1) h(-1) from N(2) reduction.

134 P <20 nmol/L, and insufficiency as PLP 20-30 nmol/L.

135 ectrosynthetic experiments produced 209+/-30 nmol NH(3) nmol MoFe(-1) h(-1) from N(2) reduction.

136 line receptor antibodies in the serum (21.30 nmol/L) and P/Q-type voltage-gated calcium channel antib

137 C-BMT-136088 specific binding were 73 +/- 30 nmol/kg and 28 +/- 12 nM, respectively.

138 tivity during isoproterenol perfusion (at 30 nmol/L, n=7/12 and 100 nmol/L n=8/12 hearts without EADs

139 re required to maintain concentrations >/=30 nmol/L during winter.

140 The prevalence of vitamin D deficiency (< 30 nmol/L) and insufficiency (< 50 nmol/L) were 1.7% (95% C

141 t of patients were vitamin D deficient (< 30 nmol/L) before planned chemotherapy.

142 ) as serum 25-hydroxyvitamin D [25(OH)D] <30 nmol/L and <50 nmol/L, respectively, in 31,841 children

143 age with "deficient" cord blood (25(OH)D <30 nmol/L) had a mean dmft score twice as high as children

144 ed the prevalence at risk of deficiency (<30 nmol/L) or prevalence at risk of inadequacy (30-49 nmol/

145 mille) with on-column analyte amount over 30 nmol N.

146 igher risks of melanoma (SRR (95% CI) per 30 nmol = 1.42 (1.17-1.72)) and keratinocyte cancer (KC) (S

147 eratinocyte cancer (KC) (SRR (95% CI) per 30 nmol/L = 1.30 (1.13-1.49)).

148 The SRR (95% CI) per 30 nmol/L increase in 25(OH) D level was 1.41 (1.19-1.67),

149 of serum 25(OH)D concentration less than 30 nmol/L; 34.22% (26.22-43.68) for a cutoff of less than 5

150 ured delta(15)N value) was confirmed when 30 nmol N was injected on-column, with the direction of dev

151 test animals with very low dose levels (300 nmol/kg) following a convenient once a week schedule.

152 lic acid, APOE reached a concentration of 32 nmol/L in epithelial lining fluid, with associated incre

153 p[a]) levels, evolocumab reduced Lp(a) by 33 nmol/L and risk of VTE by 48% (HR, 0.52 [95% CI, 0.30-0.

154 otochemically induced sediment flux was 3509 nmol m(-2) y(-1) for Ce, corresponding to 42% of the REE

155 ndrites ranging from 50 +/- 1 to 2472 +/- 38 nmol.g(-1), which relates to the degree of aqueous alter

156 m concentrations in the cerebellum were 3.38 nmol/g (gadodiamide), 2.13 nmol/g (gadopentetate dimeglu

157 ated its basal ATPase activity from 21 to 38 nmol of Pi.mg(-1).min(-1), and ATPase activity was furth

158 The mean +/- SE 25(OH)D was 65.1 +/- 0.4 nmol/L.

159 activity in AF extract corresponding to 1.4 nmol EEQ/L, 76.6 pmol DHT-EQ/L, and 10.1 pmol TEQ/L, res

160 Low TT (<10.4 nmol/L) was more prevalent in participants with SVR comp

161 95% CI: 1.4, 11.7 mug/L; P = 0.013) and 16.4 nmol/L (95% CI: 9.5, 21.4 nmol/L; P < 0.001), respective

162 ee controls (median baseline vitamin D, 21.4 nmol/L v 35.5 nmol/L; proportion with vitamin D deficien

163 = 0.013) and 16.4 nmol/L (95% CI: 9.5, 21.4 nmol/L; P < 0.001), respectively.

164 Mean mUFC at baseline was 671.4 nmol/24 h (243.3 mug/24 h), which is 4.9 times the upper

165 levels of 25(OH)D were 76.3, 76.7, and 77.4 nmol/L for the 400-IU group; 81.3, 115.3, and 132.2 for

166 I tissues (toxicity tissue; AUC(0- t) = 0.45 nmol h/g).

167 peritoneal injections of adropin(34-76) (450 nmol/kg/injection) over a 48-h period.

168 to LFLC while odds of having large-LDL <450 nmol/L in the HFHC group was 1.91 (95% CI: 1.06, 3.44) m

169 een-group difference (95% CI): 266 (77, 455) nmol.min-1.kg-1.180 min; P = 0.01; eta2p = 0.44].

170 in those with active uveitis (n = 74) was 46 nmol/l (interquartile range [IQR], 29-70 nmol/l), signif

171 nce of 0.67 nmol/mmol (95% CI, -1.13 to 2.48 nmol/mmol; P = .46).

172 ed (1)H sensitivity (nLOD(omega)(600) = 1.49 nmol s(1/2)) close to that of double strip lines, which

173 ) or prevalence at risk of inadequacy (30-49 nmol/L) by age, sex, race and Hispanic origin, and dieta

174 Participants with <=0.5 nmol/L circulating phylloquinone had an adjusted 19% hig

175 sting blood samples and categorized as <=0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L.

176 d HR (95% CI) relative to >1.0 nmol/L: <=0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L, 1.02 (0.86,

177 to -93 muM, where a low detection limit 12.5 nmol L(-1), and 48.8 nmol L(-1) were recorded by guanine

178 um 25-hydroxyvitamin D concentrations (154.5 nmol/L vs. 15.2 nmol/L in active vs. placebo arms, respe

179 lar among the glucose concentrations at ~2.5 nmol/g of heart protein/min, representing ~0.003-0.006%

180 t on the calculated HBP flux at ~2.3 and 2.5 nmol/g of heart protein/min, respectively.

181 Very similar concentrations of LK (0.5-2.5 nmol/g tissue) were found in LanCL1 knock-out, TKO and w

182 APOE at concentrations of less than 2.5 nmol/L, which are similar to levels found in epithelial

183 ntrations within the target range of 1.4-2.5 nmol/L.

184 nts with asthma (20.9 nmol/L) and COPD (21.5 nmol/L) was lower than in control subjects (39.8 nmol/L;

185 was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showed significant month

186 lin (14.0 +/- 1.6 compared with 26.8 +/- 3.5 nmol x min/L) incremental area-under-the-curve and delay

187 edian baseline vitamin D, 21.4 nmol/L v 35.5 nmol/L; proportion with vitamin D deficiency, 68% v 41%;

188 30.0 nmol/L, with status increasing by 70.5 nmol/L and 5.3 nmol/L, respectively (between-group diffe

189 lower in China than in the US (45.1 vs. 83.5 nmol/L), with Chinese elderly lower than American elderl

190 ratio, whereas a higher metformin dose (>=5 nmol/mg) caused a more reduced mitochondrial NADH/NAD st

191 increased risks of thyroid cancer [HR per 5 nmol/L higher concentration 1.18; 95% confidence interva

192 (imputed) of 1.02 (95% CI: 1.00, 1.04) per 5-nmol/L increase.

193 H)D] was measured and a level of under 30/50 nmol/L was defined as vitamin D severe deficiency/defici

194 ed by cotreatment with the alphaAnalogue (50 nmol.kg(-1).d(-1), SC, at a dose selected for lack of lo

195 using 95% prediction intervals for 30 and 50 nmol S-25(OH)D/L, intakes of 6 and 20 mug/d are required

196 d, respectively, to maintain S-25(OH)D >/=50 nmol/L, whereas intakes of 6 and 14 mug/d, respectively,

197 25-hydroxyvitamin D [S-25(OH)D; i.e., >/=50 nmol/L] during winter regardless of latitude and skin co

198 CI: 1.02, 1.75) as compared with 25OHD >= 50 nmol/L.

199 th sufficient vitamin D concentrations (>=50 nmol/L) and a high magnesium intake (median split) (HR:

200 49) as compared with 25OHD sufficiency (>=50 nmol/L).

201 lts with type 2 diabetes, serum 25(OH)D < 50 nmol/L was associated with an increased risk of a coexis

202 ciency (< 30 nmol/L) and insufficiency (< 50 nmol/L) were 1.7% (95% CI 1.0, 2.8) and 16% (95% CI 12,

203 efined vitamin D deficiency as 25-(OH)D < 50 nmol/L, insufficiency as 50-75 nmol/L, and sufficiency a

204 ups, including those with baseline 25OHD <50 nmol/L and in analyses of the upper/lower components of

205 s, including those with baseline 25(OH)D <50 nmol/L and in analyses of the upper/lower components of

206 h patients who were vitamin D deficient (<50 nmol/L) and had a low magnesium intake.

207 hers, maternal 25OHD insufficiency (25 - <50 nmol/L) at ~11 weeks gestation was associated with 1.58

208 oncentration, averaged across pregnancy, <50 nmol/L) was not associated with changes in BMD or BMC.

209 iabetes and suboptimal vitamin D status (<50 nmol/L).

210 ydroxyvitamin D [25(OH)D] <30 nmol/L and <50 nmol/L, respectively, in 31,841 children aged 1 to <18 y

211 OH)D] level was 63 (24) nmol/L; 25% were <50 nmol/L.

212 5OHD) level was 63 (24) nmol/L; 25% were <50 nmol/L.

213 ive protein <10 mg/L) and VDD as 25(OH)D <50 nmol/L.

214 xyvitamin D level, <20 ng per milliliter [50 nmol per liter]) confirmed by subsequent testing and wer

215 tween 60 and 85 nmol/L 25(OH)D (reference 50 nmol/L).

216 % of women had serum 25(OH)D of less than 50 nmol/L, with the lowest levels being found in young adul

217 % (26.22-43.68) for a cutoff of less than 50 nmol/L; and 59.54% (51.32-67.50) for a cutoff of less th

218 contusion SCI, we demonstrate that DHA (500 nmol/kg) administered acutely post-injury confers neurop

219 ns of different concentrations of H56 in 500 nmol of IC31 to enable dose selection for further vaccin

220 averine treatment of Balb/c female mice (500 nmol/kg p.o. q.d.) grafted with 4T1 breast cancer cells

221 were folate deficient (plasma folate < 4.53 nmol/L).

222 was 46.9+/-23.2 ng per milliliter (117+/-58 nmol per liter) in the vitamin D group and 11.4+/-5.6 ng

223 1 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), with a mean difference o

224 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L, respectively, but decreased to 49.8 and 93.2 nmo

225 thout PVT, with an average difference of 1.6 nmol/l p < 0.01 (95% CI - 2.54 to - 0.66), red cell fola

226 in the six groups ranged from 204.5 to 246.6 nmol per liter.

227 total T(4) concentrations decreased by 31.6 nmol/L (28.0-35.2; p<0.0001) and reverse T(3) by 0.08 nm

228 % CI - 2.54 to - 0.66), red cell folate 33.6 nmol/l p < 0.001 (95% CI - 43.64 to - 23.55) and albumin

229 persons aged >=1 y (38.7 compared with 40.6 nmol/L) and in women (35.3 compared with 37.0 nmol/L), w

230 a borderline low level of testosterone (7.6 nmol/L; normal range, 8.0-29.0 nmol/L).

231 oses 0.01 and 0.03 nmol/kg) versus KP54 (9.6 nmol/kg) in the follicular phase of healthy women (n = 9

232 ized to receive grass allergen peptides at 6 nmol at 2-week intervals for a total of 8 doses (8x6Q2W)

233 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L higher than nonconsumers (n = 229) (14 nmol/L; 95

234 ns with GO being more reactive (23.8 and 8.6 nmoles/mg protein in LAC and MP respectively after 6 h)

235 were observed for the group receiving one 6-nmol intradermal injection every 2 weeks for 14 weeks at

236 TC was observed in the group receiving one 6-nmol intradermal injection every 2 weeks for 14 weeks gr

237 tion in surface waters decreases below 50-60 nmol.kg(-1) In situ observations and model simulations s

238 r caused the removal of total mercury by 600 nmol m(-2) and of methylmercury by 214 nmol m(-2) in the

239 upling and ROS excess occurred at PCoA > 600 nmol/mg mito prot, in both control and diabetic animals.

240 evels than the local population median of 62 nmol/l (IQR, 46-77 nmol/l).

241 3 years, while those on placebo stayed at 63 nmol/L.

242 years, while those on placebo remained at 63 nmol/L.

243 in the inactive control group (n = 77) at 64 nmol/l (IQR, 52-79 nmol/l; P < 0.001).

244 women: 36.88 +/- 4.11 vs men: 21.22 +/- 3.65 nmol/g protein, p = 0.007) was observed.

245 7 nmol/mmol), with a mean difference of 0.67 nmol/mmol (95% CI, -1.13 to 2.48 nmol/mmol; P = .46).

246 hour UFC excretion: 6.91 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), w

247 al testosterone less than 250 ng/dL (or 8.67 nmol/L) and luteinizing hormone greater than 9.85 IU/L,

248 A higher precursor concentration (0.7 nmol) further increased labeling and quantitative yields

249 tlantic Bight (20 +/- 8.8 versus 2.2 +/- 1.7 nmol L(-1) d(-1) , p = 0.026) but not the Gulf of Alaska

250 ol/L (95% CI: -26.2, -7.1); CA vs. CC: -10.7 nmol/L (95% CI: -14.9, -6.5)).

251 fidence interval for difference, 125.9-154.7 nmol/L; P < 0.001) but did not influence time to sputum

252 88 functional polymorphism (AA vs. CC: -16.7 nmol/L (95% CI: -26.2, -7.1); CA vs. CC: -10.7 nmol/L (9

253 ignificant (19.4 +/- 4.8 versus 12.0 +/- 2.7 nmol L(-1) d(-1) , p > 0.05).

254 25(OH)D was 50.3 nmol/L (95% CI: 49.8, 50.7 nmol/L).

255 ) levels, evolocumab reduced Lp(a) by only 7 nmol/L and had no effect on VTE risk (P(interaction) 0.0

256 An even higher sensitivity, 7 nmol L(-1), was noted for 4-AP.

257 46 nmol/l (interquartile range [IQR], 29-70 nmol/l), significantly lower than in the inactive contro

258 tamin D [25(OH)D] concentrations of 15-50/70 nmol/L (depending on season).

259 The 90th percentile for serum (~70 nmol/L) and RBC (~1800 nmol/L) folate in supplement nonu

260 te insufficiency prevalence (RBC folate <748 nmol/L; NTD risk) in women decreased from 2007-2010 (23.

261 25-(OH)D < 50 nmol/L, insufficiency as 50-75 nmol/L, and sufficiency as >75nmol/L.

262 compared with individuals with 25(OH)D >= 75 nmol/L.

263 % (51.32-67.50) for a cutoff of less than 75 nmol/L.

264 l population median of 62 nmol/l (IQR, 46-77 nmol/l).

265 overall mean 25(OH)D concentration was 67.78 nmol/L (95% CI 64.50-71.06).

266 trol group (n = 77) at 64 nmol/l (IQR, 52-79 nmol/l; P < 0.001).

267 d ranged from 1.0-7.1, 1.4-4.8, and 0.25-2.8 nmol L(-1) for acetaldehyde, glyoxal, and methylglyoxal,

268 ection and quantification were 12.5 and 37.8 nmol/L adenine, respectively.

269 /L) was lower than in control subjects (39.8 nmol/L; P = 0.001).

270 ow detection limit 12.5 nmol L(-1), and 48.8 nmol L(-1) were recorded by guanine and adenine respecti

271 Salivary cortisol (6.8 nmol/l, P < 0.001) and heart rate (7.2 beats/min, P = 0.

272 (between-group difference in vitamin D: 65.8 nmol/L; 95% CI: 54.2, 77.3 nmol/L; P < 0.01), after supp

273 ometric mean of 25OHD concentration was 66.8 nmol/L.

274 trols) and high-dose subgroups (37.2 +/- 7.8 nmol x min(-1) x g(-1), P < 0.01 vs. controls, P < 0.05

275 om 4.97 nmol/L (SD 1.55) at baseline to 1.82 nmol/L (0.69) at month 12 (mean decrease 3.15 nmol/L, 95

276 ntly reduced melanoma risk between 60 and 85 nmol/L 25(OH)D (reference 50 nmol/L).

277 timated methane oxidation rates of up to 871 nmol of methane per gram sediment per day.

278 in D supplement use of >/=1,000 IU/day (18.9 nmol/L (95% confidence interval (CI): 16.1, 21.8) vs. no

279 entration for all subjects was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] a

280 reactive protein level of 203.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

281 reactive protein level of 203.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

282 D increase in participants with asthma (20.9 nmol/L) and COPD (21.5 nmol/L) was lower than in control

283 ct formation by an enzyme) (21.3 versus 44.9 nmol/min/mg) and lower Km (substrate concentration at wh

284 4h): 27.7 +/- 7.9 compared with 58.4 +/- 7.9 nmol/L x h, respectively; P = 0.01].

285 this value in the standard-dose (27.9 +/- 9 nmol x min(-1) x g(-1), P < 0.05 vs. controls) and high-

286 nmol/g (gadopentetate dimeglumine), and 1.91 nmol/g (gadobenate dimeglumine).

287 no difference in 24-hour UFC excretion: 6.91 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD

288 O detection with a low detection limit (3.97 nmol), a wide sensing range (0.01-100 muM), and desirabl

289 Serum T(3) concentration decreased from 4.97 nmol/L (SD 1.55) at baseline to 1.82 nmol/L (0.69) at mo

290 /L or higher (or concentrations of 0.50-0.99 nmol/L if diagnosis was confirmed by positive edrophoniu

291 precursors were compared to total fluorine (nmol F/cm(2)) determined by particle-induced gamma ray e

292 cyanopeptide concentrations ranged from high nmol to mumol g(dry)(-1) with slightly higher cell quota

293 0.89; 0.97) per every natural logarithm (Ln)-nmol/L-unit increase in circulating phylloquinone.

294 erval [CI], -.37, -.05) and N+WSH (-0.20 log nmol/L; 95% CI, -.34, -.06) interventions; similar reduc

295 eopterin was reduced by nutrition (-0.21 log nmol/L; 95% confidence interval [CI], -.37, -.05) and N+

296 and molar activity of approximately 14.0 MBq nmol(-1) Both radiotracers were immunoreactive and stabl

297 nd a molar activity of approximately 1.5 MBq nmol(-1) Reaction optimization improved the radiochemica

298 %) and apparent molar activity (22 +/- 4 Mbq/nmol) suitable for the radiolabeling of DOTA-conjugated

299 , with molar activity of more than 0.925 MBq/nmol.

300 /- 6054, n = 3, all values expressed as mean nmol/g protein +/- standard error of the mean, p = 0.040

301 ia-specific mAb that retained low nanomolar (nmol/L) target affinity and exhibited exquisite selectiv

302 tures at a sample consumption rate less than nmol/min.